Clinical disease and lung lesions in calves experimentally inoculated with Histophilus somni five days after metaphylactic administration of tildipirosin or tulathromycin

Am J Vet Res. 2016 Apr;77(4):358-66. doi: 10.2460/ajvr.77.4.358.

Abstract

Objective: To compare clinical disease and lung lesions in calves experimentally inoculated with Histophilus somni 5 days after metaphylactic administration of tildipirosin or tulathromycin. ANIMALS Twenty-four 3-month-old Holstein and Holstein-crossbreed steers.

Procedures: Calves were randomly allocated to 3 groups of 8 calves. On day 0, calves in group 1 received tildipirosin (4 mg/kg, SC), calves in group 2 received tulathromycin (2.5 mg/kg, SC), and calves in group 3 received isotonic saline (0.9% NaCl) solution (1 mL/45 kg, SC; control). On day 5, calves were inoculated with 10 mL of a solution containing H somni strain 7735 (1.6 × 10(9) CFUs/mL, intrabronchially; challenge). Calves were clinically evaluated on days 5 through 8 and euthanized on day 8. The lungs were grossly evaluated for evidence of pneumonia, and bronchial secretion samples underwent bacteriologic culture.

Results: The mean clinical score for each group was significantly increased 12 hours after challenge, compared with that immediately before challenge, and was significantly lower for tildipirosin-treated calves on days 6, 7, and 8, compared with those for tulathromycin-treated and control calves. The mean percentage of lung consolidation for tildipirosin-treated calves was significantly lower than those for tulathromycin-treated and control calves. Histophilus somni was isolated from the bronchial secretions of some tulathromycin-treated and control calves but was not isolated from tildipirosin-treated calves.

Conclusions and clinical relevance: Results indicated that metaphylactic administration of tildipirosin to calves 5 days prior to H somni challenge prevented subsequent culture of the pathogen from bronchial secretions and was more effective in minimizing clinical disease and lung lesions than was metaphylactic administration of tulathromycin.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Cattle
  • Cattle Diseases / drug therapy*
  • Cattle Diseases / microbiology
  • Cattle Diseases / pathology
  • Disaccharides / administration & dosage
  • Disaccharides / therapeutic use*
  • Heterocyclic Compounds / administration & dosage
  • Heterocyclic Compounds / therapeutic use*
  • Pasteurellaceae Infections / drug therapy
  • Pasteurellaceae Infections / veterinary*
  • Pasteurellaceae*
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / pathology
  • Pneumonia, Bacterial / veterinary*
  • Treatment Outcome
  • Tylosin / administration & dosage
  • Tylosin / analogs & derivatives*
  • Tylosin / therapeutic use

Substances

  • 20,23-dipiperidinyl-mycaminosyl-tylonolide
  • Disaccharides
  • Heterocyclic Compounds
  • tulathromycin
  • Tylosin